Skip to content

Muscle Recovery After Critical Illness

Cellular and Physical Function Outcomes Leading to Failed Muscle Recovery After Critical Illness/Muscle and Physical Functional Recovery After Acute Critical Illness

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05537298
Acronym
TRACER
Enrollment
209
Registered
2022-09-13
Start date
2022-10-18
Completion date
2027-08-01
Last updated
2026-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Critical Illness, ICU Acquired Weakness, Muscle Weakness, Post Intensive Care Unit Syndrome

Keywords

skeletal muscle, physical function

Brief summary

The overarching goal of the proposed study is to determine the trajectories of physical recovery and cellular markers involved with the underlying failure to recover muscle after critical illness, while exploring which characteristics are associated with sustained physical disability. This proposal will examine muscle pathophysiology carefully aligned with physical function outcomes in order to longitudinally assess the recovery, or failed recovery, of muscle function in participants after critical illness: 1. to examine the recovery of muscle and physical function in ICU survivors through longitudinal assessments 2. to investigate the underlying cellular markers and mechanisms of muscle recovery in ICU survivors 3. to determine which cellular markers contribute to physical disability in ICU survivors up to 1 year after hospital admission

Detailed description

Patients surviving critical illness develop significant impairments in skeletal muscle, commonly referred to as ICU-acquired weakness (ICUAW)\[8-10\]. It is estimated that up to 70-80% of patients admitted to ICU will develop some degree of neuromuscular dysfunction, weakness, myopathy or atrophy \[11,12\]. ICUAW encompasses muscle impairments that develop as a direct result of admission for critical illness\[13\] and is an independent predictor of mortality and long-term functional impairments\[14-19\]. Interventions to mitigate muscle deficits and improve physical function are a critical area of rehabilitation because of the high prevalence of short- and long-term impairments. ICU survivorship is particularly important as roughly 6 million Americans will survive an acute admission to the ICU this year alone.\[24-26\] Survivors of critical illnesses such as sepsis, viral-illnesses including coronaviruses, and acute respiratory failure (ARF) have reduced quality of life, lost wages from inability to return to work and increased caregiver and healthcare burden for years after hospital discharge.\[27-31\] Impairments in skeletal muscle are known contributors to physical disability and specifically prevent the performance of simple daily life activities like standing up from a chair. However, very little is known about cellular mechanisms leading to muscle and physical dysfunction in patients surviving critical illness during recovery. These gaps in knowledge are significant because identifying the phenotypes and underlying cellular mechanisms that lead to impaired muscle and physical function will facilitate the development of pharmacologic and non-pharmacologic interventions to mitigate or reverse disability. From a scientific perspective, this proposal is noteworthy because it will be the first to assess muscle protein synthesis rates in combination with cellular phenotypes, muscle strength, and physical function in patients recovering from an ICU admission. Studying muscle at the cellular level and integrating that knowledge with physical function will help improve our understanding of why certain patients fail to recover. Elucidating cellular mechanisms during recovery phase will provide the framework to develop interventions in subsequent studies. We will assess measures of muscle and physical function in the first year of recovery to establish why some patients have restored function, yet others have sustained disability. Improved classification of muscle dysfunction and physical function enables future studies to employ a targeted approach instead of the historical rehabilitation approach of one-size-fits-all. Specifically, the cellular findings will lead to development of novel interventions specifically designed for the underlying mechanisms, while identification of the recovery trajectories will enhance clinicians' ability to implement interventions to patients with the greatest need.

Interventions

None listed

Sponsors

Esther Dupont-Versteegden
Lead SponsorOTHER
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
CollaboratorNIH
Oklahoma Medical Research Foundation
CollaboratorOTHER
University of Alabama at Birmingham
CollaboratorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
MALE
Age
18 Years to No maximum

Inclusion criteria

* adult (\>18 y/o) * admission for sepsis or acute respiratory failure with at least 72 hour stay in ICU

Exclusion criteria

* patients who were not ambulatory prior to ICU admission * experienced \>2 ICU admissions in the past year (chronic or recurrent critical illness due to the same or different reason * patients not expected to survive \~6months after admission * acute or chronic neurologic condition * acute or chronic orthopedic condition preventing strength/functional testing * morbid obesity \>50 kg/m2 due to distortion of muscle ultrasonography

Design outcomes

Primary

MeasureTime frameDescription
Physical functionthe change from baseline to 12-monthsShort Physical Performance Battery
Mitochondrial functionthe change from baseline to 12-monthsmuscle mitochondrial respirometry
Muscle powerthe change from baseline to 12-monthslower-extremity muscle power (unilateral leg-press to record Watts)

Secondary

MeasureTime frameDescription
Physical activitythe change from baseline to 12-monthsactigraphy measuring steps per day
Functional mobilitythe change from baseline to 12-monthstimed-up and go test
Cardiopulmonary endurance / exercise capacitythe change from baseline to 12-months6-minute walk test
self-reported health-related quality of lifethe change from baseline to 12-monthsEuroQol-5Domains (EQ-5D) visual analog scale is a self-report of quality of life (0-100) with higher scores indicating a better perception of quality of life
Muscle strengththe change from baseline to 12-monthslower-extremity muscle strength measured by hand-held dynamometry (kilogram of force)
Muscle morphology #1the change from baseline to 12-monthsmyofiber size
Muscle morphology #2the change from baseline to 12-monthsmyofiber type

Countries

United States

Contacts

CONTACTKirby P Mayer, PhD
kpmaye2@uky.edu859-218-0596
CONTACTDoug Long, MS
delong2@uky.edu859-32-5438
STUDY_DIRECTORKirby P Mayer, PhD

University of Kentucky

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 27, 2026